Evidence map›Paper›PMID 34103665›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features.

Natalie M Rizzo, Lynette M Sholl, Muhammad T Idrees, John C Cheville, Sounak Gupta, Kristine M Cornejo, Hiroshi Miyamoto, Michelle S Hirsch, Katrina Collins, Andrés M Acosta

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Case Report: Malignant Interstitial Cell Tumor with Pulmonary Metastases in an Aging Naïve Fischer 344 Rat.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Clinicopathologic and molecular spectrum of testicular sex cord-stromal tumors not amenable to specific histopathologic subclassification.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  11. Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Natalie M RizzoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9532-9735
Muhammad T IdreesDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
John C ChevilleDepartment of Pathology, Mayo Clinic, Mayo Clinic Alix School of Medicine, Rochester, MN, USA.
Sounak GuptaDepartment of Pathology, Mayo Clinic, Mayo Clinic Alix School of Medicine, Rochester, MN, USA.
Kristine M CornejoDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9490-8583
Hiroshi MiyamotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.ORCID 0000-0001-7610-7769
Michelle S HirschDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8767-8564
Katrina CollinsDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Andrés M AcostaDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. aacosta4@bwh.harvard.edu.
Brigham and Women's Hospital · USIndiana University School of MedicineMayo Clinic in Arizona · USHarvard University · USUniversity of Rochester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testicular Leydig cell tumor (LCT), the most common sex-cord stromal tumor in men, represents a small fraction of all testicular tumors (~1 to 3%). Although most testicular LCTs are indolent and cured by radical orchiectomy, 5-10% have aggressive biology and metastatic potential. In primary LCTs, large size, cytologic atypia, necrosis, increased mitotic activity, and vascular invasion have been associated with clinically aggressive tumors. From a molecular perspective, the characteristics of aggressive LCTs and the differences between aggressive and nonaggressive LCTs remain largely unexplored. This study compares the genomic landscape of aggressive and nonaggressive testicular LCTs. Twenty-six cases were analyzed using next-generation DNA sequencing (NGS) and immunohistochemistry. Cases were classified as aggressive LCT if they met published criteria for malignancy in primary (i.e., testicular) tumors or if they had pathology-proven metastatic disease; otherwise, cases were considered nonaggressive. This multi-institutional series included 18 aggressive LCTs (14 primary/testicular, 4 metastatic) and 8 nonaggressive LCTs. Two cases (2/26, 8%; both aggressive LCTs) failed sequencing and had negative (i.e., uninformative) FH immunohistochemistry results. One additional primary aggressive LCT failed sequencing but had informative FH immunohistochemistry results. Combined NGS and immunohistochemical analysis demonstrated FH inactivation in 5/26 cases (19%). In addition, NGS demonstrated CTNNB1 mutations or biallelic APC inactivation in 9/23 cases (39%), copy number changes without recurrent mutations in 6/23 (26%) cases, and no alterations in 4/23 cases (17%). CTNNB1 mutations were present in both aggressive and nonaggressive LCTs. In contrast, FH inactivation and multiple copy number changes were only identified in aggressive LCTs. In conclusion, three distinct subgroups of aggressive LCTs were characterized by FH inactivation, Wnt pathway activation, and copy number changes without recurrent mutations, respectively. Nuclear translocation of β-catenin and Wnt pathway activation appear to be early driver events that provide an environment conducive for progression to aggressive biology in a subset of LCTs.

Indexed as

AdultAgedHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryLeydig Cell TumorMaleMiddle AgedMutationTesticular NeoplasmsTestisYoung Adult

Identifiers

PMID34103665
OpenAlexW3167738268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.